A Validated Model to Predict Severe Weight Loss in Amyotrophic Lateral Sclerosis
ABSTRACT Severe weight loss in amyotrophic lateral sclerosis (ALS) is common, multifactorial, and associated with shortened survival. Using longitudinal weight data from over 6000 patients with ALS across three cohorts, we built an accelerated failure time model to predict the risk of future severe (≥ 10%) weight loss using five single‐timepoint ...
David G. Lester+4 more
wiley +1 more source
Urinary mutagenicity as a biomarker in workers exposed to benzidine: correlation with urinary metabolites and urothelial DNA adducts [PDF]
Douglas J. DeMarini
openalex +1 more source
Identification of Dementia With Lewy Bodies by Skin Biopsy in Recent‐Onset Cognitive Impairment
ABSTRACT Immunofluorescence for phosphorylated alpha‐synuclein in skin biopsy samples is an emerging biomarker in synucleinopathies comprising Dementia with Lewy bodies. In this pilot study, 19 patients with recent‐onset (≤ 18 months) cognitive impairment underwent skin biopsy at baseline, with follow‐up clinical re‐evaluation.
Alessandro Furia+13 more
wiley +1 more source
Digital Activity Markers in Chronic Inflammatory Demyelinating Polyneuropathy
ABSTRACT Objective To evaluate the utility of smartwatch and smartphone‐based activity metrics for assessing disease severity and quality of life in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Methods In the electronic monitoring of disease activity in patients with CIDP (EMDA‐CIDP) trial, we performed a prospective ...
Lars Masanneck+15 more
wiley +1 more source
The current state of imaging biomarker development and evaluation. [PDF]
Halligan S, Mallett S.
europepmc +1 more source
Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring [PDF]
Ronald Lieberman+5 more
openalex +1 more source
Circulating Interleukin‐6 Levels and Timing of Acute Ischemic Stroke Onset
ABSTRACT Intravenous thrombolysis is the most widely available effective ischemic stroke treatment, but is approved only if given within 4.5 h from stroke onset. Many patients are not treated because stroke onset time is unknown. We evaluated the cytokine interleukin 6 (IL‐6) in circulating blood after acute ischemic stroke (AIS).
Robert G. Kowalski+15 more
wiley +1 more source
It is time to share Alzheimer biomarker results in dementia with Lewy bodies. [PDF]
Armstrong MJ, Grill JD, Tropea TF.
europepmc +1 more source
DNA Damage-Inducible Genes as Biomarkers for Exposures to Environmental Agents
Neil Johnson+3 more
openalex +1 more source